Disclosed is the use of an effective amount of CD271+ mesenchymal stem cell (MSC) precursor cells isolated from bone marrow of a subject and cultured under non-adherent conditions, in the manufacture of a medicament for the therapeutic treatment or prevention of a cardiovascular disease or disorder, wherein the CD271+MSC precursor cells are capable of engrafting in a heart in vivo in infarct and border zones.